succinate dehydrogenase complex iron sulfur subunit BGenealiases: CWS2 · IP · MC2DN4 · PGL4 · PPGL4 · SDH
Q-omics provides the consensus-scored SDHB profile across patient tissues and cancer cell-line models. SDHB expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SDHB is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, SDHB protein abundance shows 19,941 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRP, and GBM as cancer lineages where SDHB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDHB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDHB survival associations across molecular data types. SDHB RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDHB RNA expression–survival associations across cancer types. High SDHB expression shows unfavorable associations in ACC, LAML, HNSC and UCEC, but favorable associations in KIRC and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SDHB RNA expression.
This table summarizes SDHB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SDHB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDHB shows lower tumor expression in KIRP, KIRC, COAD, THCA and KICH and higher tumor expression in BLCA. The KIRP box plot shows higher SDHB RNA expression in normal versus tumor tissue (log2 FC = −0.913, t-test p < 0.001).
This table shows molecular features associated with SDHB in patient tissues and cancer cell lines. In patient samples, SDHB shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SDHB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
